PILL.CN - Canntab Therapeutics Limited

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.7800
-0.0200 (-2.50%)
At close: 1:41PM EDT
Stock chart is not supported by your current browser
Previous Close0.8000
Open0.0000
Bid0.7700 x 0
Ask0.8000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume26,636
Market Cap24.544M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-0.0860
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar. 08, 2016
1y Target EstN/A
  • CNW Group

    IIROC Trade Resumption - PILL

    VANCOUVER, BC , June 2, 2020 /CNW/ - Trading resumes in: Company:  Canntab Therapeutics Limited CSE Symbol: PILL (all issues) Resumption (ET): 11:45 AM IIROC can make a decision to impose a temporary suspension ...

  • Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement
    CNW Group

    Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement

    TORONTO, June 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs ("MediPharm") (TSX:LABS.TO - News)(OTCQX:MEDIF - News)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products. Orders under the agreement will be composed of a mix of Canntab's proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths. MediPharm will purchase and distribute cannabis products on a non-exclusive basis across Canada, through licensed provincial dispensaries.

  • CNW Group

    IIROC Trading Halt - PILL

    IIROC Trading Halt - PILL

  • Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer
    CNW Group

    Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer

    TORONTO, May 15, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the appointment of Joshi Laxminarayan as Chief Scientific Officer (CSO). In his role as CSO, Mr. Laxminarayan will be responsible for directing Canntab's strategic research and partnership program, and overseeing the Company's ongoing manufacturing and distribution operations.

  • Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference
    CNW Group

    Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference

    TORONTO , May 11, 2020 /CNW/ - Canntab Therapeutics Limited ( CSE:PILL.CN )( OTCQB:CTABF ) ( FRA:TBF1.F ) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene ...

  • Canntab Closes Final Tranche of Private Placement for Aggregate Proceeds of $3.7m
    CNW Group

    Canntab Closes Final Tranche of Private Placement for Aggregate Proceeds of $3.7m

    TORONTO, March 16, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has closed the final tranche of its previously announced non-brokered private placement (the "Private Placement") by issuing 1,291,000 units ("Units") at a price of $0.50 per Unit for gross proceeds of $645,500. Together with the funds raised under the first tranche of the Private Placement, the Company has received total gross proceeds of $3,725,500 under the Private Placement.

  • Canntab Announces Replacement of Advisor Warrants and Intention to Appoint Larry Latowsky as Director and Executive Chairman of the Board
    CNW Group

    Canntab Announces Replacement of Advisor Warrants and Intention to Appoint Larry Latowsky as Director and Executive Chairman of the Board

    TORONTO , March 6, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it intends to issue 500,000 common share purchase warrants (the "Replacement Warrants") to Larry Latowsky and that, subject to Health Canada approval, Canntab intends to appoint Larry Latowsky as a Director and Executive Chairman of the Board. Each Replacement Warrant will be exercisable at a price of $0.60 per share until March 4, 2025 . Issuance of the Replacement Warrants is subject to Mr. Latowsky's agreement to cancel an equivalent number of common share purchase warrants exercisable at a price of $1.00 per share.

  • Newsfile

    Canntab Announces Cancellation of Options and Issuance of Warrants

    Toronto, Ontario--(Newsfile Corp. - March 3, 2020) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that the Board of Directors passed a resolution to issue 1,300,000 warrants ("Warrants") to purchase common shares ("Common Shares") of the Company to employees, advisors and consultants of the Company. Each Warrant will entitle the holder to ...

  • InvestmentPitch Media Video Discusses Canntab's Receipt of its Cannabis Standard Processing and Sales for Medical Purposes Licence from Health Canada and Close of 1st Tranche of Private Placement - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses Canntab's Receipt of its Cannabis Standard Processing and Sales for Medical Purposes Licence from Health Canada and Close of 1st Tranche of Private Placement - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has received its Cannabis Standard Processing and Sales for Medical Purposes Licence from Health Canada. This follows the recent grant by Health Canada of a Cannabis Research Licence. These new licences will enable the company to submit Notice of New Cannabis ...

  • Canntab Receives Health Canada Licence and Closes $3.08M Offering
    CNW Group

    Canntab Receives Health Canada Licence and Closes $3.08M Offering

    TORONTO , March 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that on Friday, February 28 th, 2020 it successfully  received its Cannabis Standard Processing & Sales for Medical Purposes Licences from Health Canada, and that it has closed the first tranche (the "First Tranche") of its non-brokered private placement offering (the "Private Placement") for total gross proceeds of $3,080,000 .

  • InvestmentPitch Media Video Discusses Canntab's Receipt of Cannabis Research Licence from Health Canada - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses Canntab's Receipt of Cannabis Research Licence from Health Canada - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - February 25, 2020) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has been granted a Cannabis Research Licence by Health Canada. The research licence will allow Canntab to receive oil and continue research and development of the company's growing line of next generation medical cannabis solutions at the company's Markham Ontario Facility.For ...

  • Canntab Awarded Health Canada Cannabis Research Licence
    CNW Group

    Canntab Awarded Health Canada Cannabis Research Licence

    TORONTO , Feb. 24, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that Health Canada has granted the Company a Cannabis Research Licence for the purpose of continuing research and development of the Company's growing line of next generation medical cannabis solutions at the Company's Markham Ontario Facility.

  • Canntab Announces Non-Brokered Private Placement
    CNW Group

    Canntab Announces Non-Brokered Private Placement

    TORONTO , Feb. 6, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it is launching a private placement (the "Private Placement") of up to $2.5 million of units ("Units"), subject to the Company's over-allotment option to increase the size of  the Private Placement by up to an additional $1.5 million , at a price of $0.50 per Unit, with each Unit consisting of one common share and one full warrant to acquire an additional common share at a price of $0.75 per share for a period of two years. Canntab expects to close the Private Placement on or before February 20 th, 2020. Canntab's expansion through its wholly owned US subsidiary Canntab USA , Inc. into the State of Florida jointly with Exactus Inc. for the manufacture of a CBD hard pill (non-THC) in formulations for sale and distribution across the United States .

  • Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status
    CNW Group

    Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status

    The final step to obtain a licence to process Canntab's cannabis hard pill formulation, at its fully built out Markham, Ontario facility. Retains Larry Latowsky , former CEO of Katz Group Canada and its flagship holding Rexall, as an advisor in order to strengthen Canntab's commercialization efforts. TORONTO , Dec. 23, 2019 /CNW/ - Canntab Therapeutics Limited (PILL.CN) (CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces today the submission of the Company's Site Evidence Package to Health Canada for approval of their Licence Producer Status (Processing-Standard, Federal Sales-Medical).

  • GlobeNewswire

    Exactus, Inc. Enters into Supply & Distribution Agreement with Canntab Therapeutics to Produce Immediate and Extended Release Tablets

    Exactus, Inc. (EXDI) (the “Company”), an industrial hemp farm operator and manufacturer of hemp-derived phytocannabinoid products, today announced that it has entered into a supply and distribution agreement with Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) to produce immediate and extended release tablets. Exactus will provide Canntab a subleased space in their facility in Florida to equip for the purpose of manufacturing advanced hemp derived cannabinoid tablets.

  • Canntab Achieves Key Milestone: Canntab Enters Into Supply & Distribution Agreements With Exactus for the Purchase of Hemp-Derived CBD Oil and the Distribution of Canntab's Hard Pill Formulations in the United States
    CNW Group

    Canntab Achieves Key Milestone: Canntab Enters Into Supply & Distribution Agreements With Exactus for the Purchase of Hemp-Derived CBD Oil and the Distribution of Canntab's Hard Pill Formulations in the United States

    Canntab Achieves Key Milestone: Canntab Enters Into Supply & Distribution Agreements With Exactus for the Purchase of Hemp-Derived CBD Oil and the Distribution of Canntab's Hard Pill Formulations in the ...

  • Canntab to utilize the advanced BOSS extraction system from Word Class Extractions to further its own extraction capabilities
    CNW Group

    Canntab to utilize the advanced BOSS extraction system from Word Class Extractions to further its own extraction capabilities

    TORONTO, Oct. 8, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, today announced the signing of a binding Letter of Intent ("LOI") to establish a joint venture (the "Joint Venture") with World Class Extractions Inc. (CSE:PUMP) ("WCE"). Pursuant to the terms of the LOI, WCE will install certain extraction and processing systems (the "Systems") at Canntab's production facility in Markham, Ontario (the "Facility"). As a late stage applicant, Health Canada approval under the Cannabis Act is at an advanced stage, which, once obtained, will allow Canntab to process high quality cannabis derivatives at the Facility.

  • InvestmentPitch Media Video Discusses Canntab's Receipt of Initial Indication of Patentability for Immediate Release Cannabidiol Formulation - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses Canntab's Receipt of Initial Indication of Patentability for Immediate Release Cannabidiol Formulation - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 16, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation. The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not only patentable but also ...

  • Canntab Receives Initial Indication of Patentability for Immediate Release Cannabidiol Formulation
    CNW Group

    Canntab Receives Initial Indication of Patentability for Immediate Release Cannabidiol Formulation

    TORONTO, Aug. 15, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation (the "Immediate Release Formulation"). The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not only patentable but also novel, non-obvious and useful.

  • InvestmentPitch Media Video Discusses Canntab's Update of Significant Developments Including Hemp Cultivation and Gel Capsule Manufacturing - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses Canntab's Update of Significant Developments Including Hemp Cultivation and Gel Capsule Manufacturing - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 1, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has updated investors about significant developments. Canntab, with headquarters and R & D located in Markham, currently operates out of Cobourg, Ontario where the company has co-location and profit sharing agreements with its strategic partner, FSD Pharma Inc. (CSE:HUGE), a holder of both ...

  • Canntab provides corporate update
    CNW Group

    Canntab provides corporate update

    Commercial batch manufacturing of oil-filled gel capsules to begin in Cobourg, leading to a Health Canada request for authorization to begin full scale production and sale. Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status. A pharmacist and drug formulation specialist has been hired to assist with our product applications to Health Canada.